Peptide Hormones That Control Blood Glucose
Metabolic Peptides
7 peptide hormones
At least seven peptide hormones work in concert to regulate blood glucose, each secreted from different cell types and acting through distinct receptor pathways.
Seino et al., J Diabetes Investig, 2010
Seino et al., J Diabetes Investig, 2010
View as imageBlood glucose stays between 70 and 100 mg/dL in healthy humans despite meals, fasting, exercise, and sleep. This tight control depends on a network of peptide hormones, not just insulin. At least seven peptide hormones participate: insulin and amylin from beta cells, glucagon from alpha cells, somatostatin from delta cells, GLP-1 and GIP from intestinal enteroendocrine cells, and C-peptide co-released with insulin. Each acts on different tissues through different receptors, but they form an integrated system where disruption of any single player can destabilize the whole network. Understanding this map is essential for making sense of modern diabetes and obesity drugs, nearly all of which target one or more of these peptide pathways. For the broader metabolic context, see our pillar article on metabolic syndrome peptide biomarkers.
Key Takeaways
- Insulin (51 amino acids) and glucagon (29 amino acids) form the primary glucose-lowering and glucose-raising pair, both secreted from pancreatic islets
- GLP-1 and GIP are incretin hormones responsible for 50-70% of the insulin response to an oral glucose load (Seino et al., 2010)
- Amylin (37 amino acids) is co-secreted with insulin and slows gastric emptying, suppresses glucagon, and promotes satiety; cagrilintide and amycretin target this pathway (Dahl et al., Lancet, 2025)
- Somatostatin acts as a universal brake on islet hormone secretion, suppressing both insulin and glucagon release from neighboring cells
- C-peptide, long considered inert, shows emerging evidence for vascular and renal protective effects in type 2 diabetes (Lin et al., 2025)
- Every major GLP-1 agonist, dual agonist, and triple agonist drug targets one or more of these seven peptide pathways
Insulin: The Glucose-Lowering Master Regulator
Insulin is a 51-amino-acid peptide hormone consisting of an A chain (21 amino acids) and a B chain (30 amino acids) connected by two disulfide bonds. It is produced by beta cells in the pancreatic islets of Langerhans and released in response to rising blood glucose.
Insulin lowers blood glucose through three main mechanisms: it stimulates glucose uptake into skeletal muscle and adipose tissue (via GLUT4 transporter translocation), it suppresses hepatic glucose production (reducing glycogenolysis and gluconeogenesis in the liver), and it promotes glycogen synthesis for glucose storage. Insulin also inhibits lipolysis and promotes protein synthesis, connecting glucose metabolism to fat and protein metabolism.
Beta cells release insulin in a biphasic pattern. The first phase (within minutes of glucose rise) involves release of pre-formed insulin granules. The second phase (sustained over hours) requires new insulin synthesis and processing. Loss of the first phase is one of the earliest detectable abnormalities in type 2 diabetes, often appearing years before overt hyperglycemia.
Glucagon: The Counter-Regulatory Opponent
Glucagon is a 29-amino-acid peptide produced by alpha cells in the pancreatic islets. It acts primarily on the liver through the glucagon receptor (GCGR), a G protein-coupled receptor that activates cAMP-dependent signaling cascades.
When blood glucose falls, glucagon stimulates hepatic glycogenolysis (breaking down glycogen to release glucose) and gluconeogenesis (synthesizing new glucose from amino acids and other substrates). It also promotes hepatic fatty acid oxidation and ketone body production during prolonged fasting.
The insulin-glucagon ratio, rather than either hormone alone, determines the metabolic state of the liver. A high insulin-to-glucagon ratio (after a meal) promotes glucose storage. A low ratio (during fasting) promotes glucose release. In type 2 diabetes, this ratio is disrupted in both directions: insulin action is impaired (resistance) and glucagon secretion is inappropriately elevated, contributing to fasting hyperglycemia.
This dysregulation is why GLP-1 agonists are so effective: they simultaneously enhance insulin secretion and suppress glucagon secretion, correcting both sides of the ratio. For a detailed comparison of all available GLP-1 drugs, see our article on every GLP-1 receptor agonist compared.
GLP-1: The Incretin That Changed Diabetes Treatment
Glucagon-like peptide-1 (GLP-1) is a 30-amino-acid peptide produced by L-cells in the distal small intestine and colon. It is released in response to nutrients (particularly glucose and fat) reaching the gut lumen. GLP-1 belongs to a class of hormones called incretins, which amplify the insulin response to oral glucose compared to intravenous glucose.
Seino et al. (2010) established that the incretin effect, the enhanced insulin response to oral versus intravenous glucose, accounts for 50-70% of the total insulin secreted after a meal. GLP-1 and GIP together are responsible for this effect. GLP-1 acts through the GLP-1 receptor on beta cells to potentiate glucose-stimulated insulin secretion (it only works when glucose is elevated, reducing hypoglycemia risk), suppress glucagon from alpha cells, slow gastric emptying, and reduce appetite through central nervous system effects.[1]
Native GLP-1 has a half-life of approximately 2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). This limitation drove the development of DPP-4-resistant GLP-1 receptor agonists (exenatide, liraglutide, semaglutide, tirzepatide) and DPP-4 inhibitors (sitagliptin, saxagliptin) that protect endogenous GLP-1. See our article on exenatide, the first GLP-1 for the history.
Holst et al. (2013) described how incretin hormones connect glucose regulation to satiety signaling, explaining why GLP-1 agonists produce both glucose-lowering and weight loss effects: the same peptide pathway that amplifies insulin after meals also signals the brain that eating should stop.[2]
GIP: The Other Incretin
Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino-acid peptide produced by K-cells in the duodenum and jejunum. Like GLP-1, GIP potentiates glucose-stimulated insulin secretion through its own receptor (GIPR) on beta cells.
GIP was actually discovered before GLP-1, but its therapeutic development stalled because GIP also stimulates glucagon secretion (unlike GLP-1, which suppresses it) and promotes fat storage in adipose tissue. For decades, GIP was considered a less attractive drug target than GLP-1.
That changed with tirzepatide, a dual GLP-1/GIP agonist that produced greater weight loss and glucose-lowering than any pure GLP-1 agonist. The mechanism behind GIP's contribution to tirzepatide's efficacy remains debated. One hypothesis: GIP receptor activation in the brain and adipose tissue produces complementary effects that enhance the weight loss produced by GLP-1 receptor activation alone. See our article on tirzepatide's dual mechanism.
Yamanouchi et al. (2025) reviewed the roles of both incretin hormones in metabolic and cardiovascular health, concluding that GIP and GLP-1 have distinct tissue distribution patterns and signaling properties that explain why dual agonism produces effects that neither hormone achieves alone.[3]
Amylin: The Co-Secreted Modulator
Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide co-secreted with insulin from beta cells in a roughly 1:100 amylin-to-insulin ratio. It acts through amylin receptors (hetero-complexes of the calcitonin receptor with receptor activity-modifying proteins) in the area postrema and hypothalamus.
Amylin complements insulin's glucose-lowering action through three mechanisms: it slows gastric emptying (reducing the rate of glucose entry into the bloodstream), suppresses postprandial glucagon secretion (preventing inappropriate glucose release from the liver after meals), and promotes satiety (reducing food intake through central nervous system effects).
Pramlintide (Symlin) is the only approved amylin analog, used as an adjunct to insulin in type 1 and type 2 diabetes. It is administered by injection before meals and reduces postprandial glucose excursions.
The amylin pathway is now receiving renewed attention. Chung et al. (2026) reviewed five years of evidence on amylin's emerging role in treating "diabesity" (combined diabetes and obesity), noting that long-acting amylin analogs could address both glycemic control and weight management simultaneously.[4]
Dahl et al. (2025) published Phase 1b/2a results for amycretin, a novel unimolecular GLP-1 and amylin receptor agonist, in the Lancet. Amycretin produced substantial weight loss in a randomized controlled study, demonstrating that combining GLP-1 and amylin receptor activation in a single molecule is pharmacologically viable and produces additive metabolic effects.[5]
Cagrilintide, a long-acting amylin analog developed by Novo Nordisk, is being studied in combination with semaglutide (the combination is called CagriSema). Cao et al. (2025) characterized the structural and dynamic features of cagrilintide binding to both calcitonin and amylin receptors, providing molecular-level insight into how this engineered peptide achieves its long duration of action.[6]
Bailey et al. (2026) reviewed the broader pipeline of long-acting amylin-related peptides for obesity and type 2 diabetes, noting that the amylin pathway represents a complementary axis to GLP-1 that could produce greater combined effects on both glucose and body weight.[7]
Somatostatin: The Universal Brake
Somatostatin is a cyclic peptide produced by delta cells in the pancreatic islets (and by neurons throughout the brain and gut). It exists in two active forms: somatostatin-14 (14 amino acids) and somatostatin-28 (28 amino acids). Both act through five somatostatin receptor subtypes (SSTR1-5).
Within the islet, somatostatin acts as a paracrine inhibitor of both insulin and glucagon secretion. Delta cells are strategically positioned between alpha and beta cells, and somatostatin released from delta cells reaches neighboring cells at high local concentrations. This creates a local braking system that prevents excessive hormone release from either cell type.
Somatostatin also inhibits gut hormone secretion, including GLP-1 and GIP, slows gastrointestinal motility, and suppresses growth hormone release from the pituitary. Its therapeutic applications have focused on its antisecretory properties: octreotide and lanreotide (somatostatin analogs) are used to treat neuroendocrine tumors and acromegaly, not diabetes. However, the delta cell's role in islet glucose sensing is an active area of research that may reveal new therapeutic angles.
C-Peptide: From Biomarker to Potential Therapeutic
C-peptide (connecting peptide) is a 31-amino-acid peptide that is cleaved from proinsulin during insulin biosynthesis. For every molecule of insulin produced, one molecule of C-peptide is released. For decades, C-peptide was considered biologically inert, useful only as a clinical biomarker of endogenous insulin production (since exogenous insulin therapy does not contain C-peptide).
That view is changing. Lin et al. (2025) explored the potential therapeutic role of C-peptide in type 2 diabetes management, reviewing evidence that C-peptide activates specific signaling pathways in vascular endothelial cells and renal tubular cells. These effects may protect against diabetic microvascular complications (retinopathy, nephropathy, neuropathy) independently of insulin's glucose-lowering action.[8]
The clinical implication: patients with type 1 diabetes who have lost all beta cell function also lose all C-peptide production, potentially losing its protective vascular effects in addition to losing insulin. Whether C-peptide replacement (alongside insulin) could reduce microvascular complications in type 1 diabetes remains an open question.
How These Peptides Interact: The Integrated Network
These seven peptide hormones do not operate independently. They form an interconnected network with multiple feedback loops:
The incretin-insulin axis. Nutrients in the gut trigger GLP-1 and GIP release from L-cells and K-cells. These incretins reach pancreatic beta cells and amplify glucose-stimulated insulin secretion. GLP-1 also suppresses glucagon from alpha cells. This axis explains why oral glucose produces a larger insulin response than intravenous glucose (the incretin effect) and why GLP-1 agonists are so effective at lowering blood glucose.[1]
The insulin-glucagon balance. Insulin and glucagon are released from neighboring cells within the same islet and mutually regulate each other. Insulin suppresses glucagon release from alpha cells. Glucagon (at certain concentrations) stimulates insulin release. The balance between them determines whether the liver stores or releases glucose.
The amylin complement. Amylin is co-released with insulin and adds three effects that insulin alone does not provide: glucagon suppression, gastric emptying delay, and satiety signaling. This explains why insulin replacement alone does not fully normalize glucose dynamics in type 1 diabetes.
The somatostatin brake. Somatostatin from delta cells suppresses both insulin and glucagon, preventing excessive oscillation of the system. It also suppresses GLP-1 and GIP secretion from the gut, creating a feedback loop that limits incretin-driven insulin surges.
Motokura et al. (2026) demonstrated in developing rats that the incretin effect alone is sufficient for glucose control in early life, highlighting how the relative contribution of each peptide pathway shifts across development and disease states.[9]
For a deeper look at what happens when this system breaks down, see our article on insulin resistance at the molecular level. For the protective role of fat-derived peptides, see our article on adiponectin and diabetes.
Why This Map Matters for Understanding Modern Drugs
Nearly every diabetes and obesity drug on the market or in development targets one or more of these seven peptide pathways:
- Insulin analogs (glargine, lispro, aspart): replace endogenous insulin
- GLP-1 agonists (semaglutide, liraglutide, exenatide): mimic GLP-1
- GLP-1/GIP dual agonists (tirzepatide): mimic both incretins
- GLP-1/glucagon dual agonists (pemvidutide, survodutide): add direct hepatic glucagon effects
- Triple agonists (retatrutide): GLP-1 + GIP + glucagon
- Amylin analogs (pramlintide, cagrilintide): supplement amylin signaling
- GLP-1/amylin dual agonists (amycretin): combine incretin and amylin pathways
- DPP-4 inhibitors (sitagliptin): protect endogenous GLP-1 and GIP from degradation
- Somatostatin analogs (octreotide): used for neuroendocrine tumors, not diabetes
The trend in drug development is clear: targeting multiple peptide pathways simultaneously produces greater effects than targeting any single pathway. This reflects the biology, where glucose homeostasis depends on the coordinated action of all seven peptides.
The Bottom Line
Blood glucose regulation depends on at least seven peptide hormones acting through distinct receptors and feedback loops: insulin and amylin from beta cells, glucagon from alpha cells, somatostatin from delta cells, GLP-1 and GIP from intestinal cells, and C-peptide co-released with insulin. Modern diabetes and obesity drugs increasingly target multiple pathways simultaneously, with dual and triple agonists producing greater effects than single-pathway agents. Understanding this integrated peptide network is essential for interpreting both the mechanisms and side effects of GLP-1 agonists, dual agonists, and the next generation of metabolic peptide therapies.